What question did this study set out to answer?

To assess the therapeutic efficacy and cardiac safety of propafenone in suppressing serious ventricular arrhythmias using noninvasive diagnostic tools.

December 1, 1987Journal of Electrophysiology

Propafenone Therapy in Patients with Serious Ventricular Arrhythmia ‐ Noninvasive Evaluation of Efficacy

View Full Paper

Ask AI

Bookmark

Why the study?

Is propafenone effective and safe for the suppression of spontaneously occurring ventricular arrhythmia?

Population

Patients with serious ventricular arrhythmia

Design

Review

Authors

LCLAWRENCE CUENIBrigham and Women's Hospital PPPhilip J. PodridBoston University

Discussion

Member takes

Implication

Requires caution with propafenone in severe heart disease; leaves open need for randomized trials on ventricular arrhythmia suppression.

Key Points

To assess the therapeutic efficacy and cardiac safety of propafenone in suppressing serious ventricular arrhythmias using noninvasive diagnostic tools.
Evaluated arrhythmia suppression utilizing noninvasive continuous ambulatory cardiac monitoring and exercise stress testing.
Tracked the incidence of nonserious side effects, therapy discontinuation rates, and adverse cardiac events.
Propafenone effectively suppressed spontaneously occurring ventricular arrhythmias during both routine monitoring and exercise testing, preventing recurrence when tolerated.
Treatment discontinuation due to minor adverse reactions was infrequent, but serious cardiac complications—including arrhythmia aggravation, heart failure exacerbation, and conduction abnormalities—occurred mainly in patients with severe underlying heart disease.

Structured PICO

Is propafenone effective and safe for the suppression of spontaneously occurring ventricular arrhythmia?

Population

Patients with serious ventricular arrhythmia

Intervention

Propafenone

Outcome

Suppression of spontaneously occurring ventricular arrhythmia

Propafenone is an effective antiarrhythmic for ventricular arrhythmias but requires cautious use in patients with severe underlying heart disease due to risks of arrhythmia aggravation and CHF exacerbation.

Cite This Study

CUENI et al. (1987) studied this question.

synapsesocial.com/papers/6a8bd72c3fd21775a533bf08 https://doi.org/10.1111/j.1540-8167.1987.tb01447.x

View Full Paper

Ask AI

Bookmark

Propafenone Therapy in Patients with Serious Ventricular Arrhythmia ‐ Noninvasive Evaluation of Efficacy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Propafenone Therapy in Patients with Serious Ventricular Arrhythmia ‐ Noninvasive Evaluation of Efficacy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider